Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Reva K BashoClinton YamMichael GilcreaseRashmi K MurthyThorunn HelgasonDaniel D KarpFunda Meric-BernstamKenneth R HessVicente ValeroConstance AlbarracinJennifer K LittonMariana Chavez-MacGregorDavid HongRazelle KurzrockGabriel N HortobagyiFilip JankuStacy L MoulderPublished in: The oncologist (2018)
Metaplastic breast cancers (MpBCs) represent <1% of all breast cancers, demonstrate mesenchymal differentiation, and are typically resistant to chemotherapy. Patients with advanced MpBC treated with an mTOR-based systemic therapy regimen had better long-term outcomes compared with patients with nonmetaplastic triple-negative breast cancer treated with the same regimen, suggesting that metaplastic histology may predict benefit from agents targeting the PI3K/Akt/mTOR pathway.